journal article·2024-06-18Open access

Acidic Nanoparticles Restore Lysosomal Acidification and Rescue Metabolic Dysfunction in Pancreatic β-Cells under Lipotoxic Conditions

Chih Hung Lo, Lance M. O’Connor, Gavin Wen Zhao Loi, Eka Norfaishanty Saipuljumri, Jonathan Indajang, Kaitlynn M. Lopes, Orian S. Shirihai, Mark W. Grinstaff, Jialiu Zeng

ACS Nano· Volume 18· Issue 24

Abstract

Type 2 diabetes (T2D), a prevalent metabolic disorder lacking effective treatments, is associated with lysosomal acidification dysfunction, as well as autophagic and mitochondrial impairments. Here, we report a series of biodegradable poly(butylene tetrafluorosuccinate- co -succinate) polyesters, comprising a 1,4-butanediol linker and varying ratios of tetrafluorosuccinic acid (TFSA) and succinic acid as components, to engineer lysosome-acidifying nanoparticles (NPs). The synthesized NPs are spherical with diameters of ≈100 nm and have low polydispersity and good stability. Notably, TFSA NPs, which are composed entirely of TFSA, exhibit the strongest degradation capability and superior acidifying properties. We further reveal significant downregulation of lysosomal vacuolar (H+)-ATPase subunits, which are responsible for maintaining lysosomal acidification, in human T2D pancreatic islets, INS-1 β-cells under chronic lipotoxic conditions, and pancreatic tissues of high-fat-diet (HFD) mice. Treatment with TFSA NPs restores lysosomal acidification, autophagic function, and mitochondrial activity, thereby improving the pancreatic function in INS-1 cells and HFD mice with lipid overload. Importantly, the administration of TFSA NPs to HFD mice reduces insulin resistance and improves glucose clearance. These findings highlight the therapeutic potential of lysosome-acidifying TFSA NPs for T2D.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pancreatic function and diabetes · Endoplasmic Reticulum Stress and Disease · Calcium signaling and nucleotide metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Lee Kong Chian School of Medicine, Nanyang Technological University

College of Biological Sciences

University of Minnesota

Meinig School of Biomedical Engineering

Cornell University

Department of Chemistry

Boston University

Division of Endocrinology, Department of Medicine

David Geffen School of Medicine, University of California, Los Angeles

Department of Molecular and Medical Pharmacology

University of California, Los Angeles

Department of Biomedical Engineering

Funding

Momental Foundation · Nanyang Technological University

References (100+)

Show source-provided references
1. 10.2147/DMSO.S31989510.2147/DMSO.S319895 ↗
2. International Diabetes Federation, IDF Diabetes Atlas, 2021.
3. 10.1016/j.pcd.2023.03.00510.1016/j.pcd.2023.03.005 ↗
4. 10.1016/j.cmet.2021.12.01210.1016/j.cmet.2021.12.012 ↗
5. 10.1159/00048052510.1159/000480525 ↗
6. 10.1038/nrendo.2013.25610.1038/nrendo.2013.256 ↗
7. 10.1007/s00125-017-4342-z10.1007/s00125-017-4342-z ↗
8. 10.1016/j.metabol.2015.10.01410.1016/j.metabol.2015.10.014 ↗
9. 10.1080/14656566.2021.199941310.1080/14656566.2021.1999413 ↗
10. 10.5114/aoms.2015.5330410.5114/aoms.2015.53304 ↗
11. 10.1016/S0140-6736(12)61267-710.1016/S0140-6736(12)61267-7 ↗
12. 10.2147/DMSO.S700410.2147/DMSO.S7004 ↗
13. 10.1517/14656566.7.8.105510.1517/14656566.7.8.1055 ↗
14. 10.1038/nrd447710.1038/nrd4477 ↗
15. 10.1016/j.tem.2020.02.00110.1016/j.tem.2020.02.001 ↗
16. 10.1002/advs.20210246610.1002/advs.202102466 ↗
17. 10.1016/j.drudis.2022.10339310.1016/j.drudis.2022.103393 ↗
18. 10.1186/s12951-015-0136-y10.1186/s12951-015-0136-y ↗
19. 10.1074/jbc.M111.24241210.1074/jbc.M111.242412 ↗
20. 10.2337/db16-100910.2337/db16-1009 ↗
21. 10.1096/fj.201801292R10.1096/fj.201801292R ↗
22. 10.1002/adhm.20180151110.1002/adhm.201801511 ↗
23. 10.3390/cells905113110.3390/cells9051131 ↗
24. 10.1089/ars.2022.001610.1089/ars.2022.0016 ↗
25. 10.1016/j.jmb.2019.07.03010.1016/j.jmb.2019.07.030 ↗
26. 10.1083/jcb.20151104210.1083/jcb.201511042 ↗
27. 10.1186/s40035-023-00362-010.1186/s40035-023-00362-0 ↗
28. 10.36069/JoLS/2020120410.36069/JoLS/20201204 ↗
29. Carlson, J. G.; Rotto, N. T.; Anderson, J. T.; Spawn, C.L.; Blagev, A. V. Carboxylic acid functional polyurethane polymers and blends thereof used in magnetic recording media. WO1997023526A11996.
30. 10.1097/00002480-199407000-0012110.1097/00002480-199407000-00121 ↗
31. 10.1093/nar/gky103310.1093/nar/gky1033 ↗
32. 10.1295/polymj.7.46010.1295/polymj.7.460 ↗
33. 10.1039/c3nr00114h10.1039/c3nr00114h ↗
34. 10.1039/D1TB00559F10.1039/D1TB00559F ↗
35. Tyagi S. · Res. Rev.: J. Pharm. Nanotechnol. · 2016 · 4 · 2347
36. Chime S. A. · 2014
37. 10.1016/0166-6622(86)80340-710.1016/0166-6622(86)80340-7 ↗
38. 10.1016/j.ajps.2015.09.00410.1016/j.ajps.2015.09.004 ↗
39. 10.1074/jbc.M110.20029510.1074/jbc.M110.200295 ↗
40. 10.1186/s13578-022-00836-010.1186/s13578-022-00836-0 ↗
41. 10.36069/jols/2020120110.36069/jols/20201201 ↗
42. 10.1073/pnas.190367811610.1073/pnas.1903678116 ↗
43. 10.1016/j.bbrc.2011.08.04110.1016/j.bbrc.2011.08.041 ↗
44. 10.1016/j.abb.2022.10911610.1016/j.abb.2022.109116 ↗
45. 10.1016/j.mce.2004.04.01710.1016/j.mce.2004.04.017 ↗
46. 10.3389/fcell.2020.59076310.3389/fcell.2020.590763 ↗
47. 10.1080/19382014.2023.226772510.1080/19382014.2023.2267725 ↗
48. 10.1038/s41467-023-38165-610.1038/s41467-023-38165-6 ↗
49. 10.14573/altex.2010.2.10510.14573/altex.2010.2.105 ↗
50. 10.1038/s41580-020-00317-710.1038/s41580-020-00317-7 ↗
51. 10.1152/ajpcell.00466.202010.1152/ajpcell.00466.2020 ↗
52. 10.1080/15548627.2021.201600410.1080/15548627.2021.2016004 ↗
53. 10.1080/15548627.2020.179728010.1080/15548627.2020.1797280 ↗
54. 10.1038/embor.2013.16810.1038/embor.2013.168 ↗
55. 10.1016/j.redox.2021.10202610.1016/j.redox.2021.102026 ↗
56. 10.3389/fnut.2021.66383810.3389/fnut.2021.663838 ↗
57. 10.2337/diabetes.53.suppl_3.s21510.2337/diabetes.53.suppl_3.s215 ↗
58. 10.1172/JCI1076110.1172/JCI10761 ↗
59. Wilcox G. · Clin. Biochem. Rev. · 2005 · 26 · 19
60. 10.1371/journal.pone.020518010.1371/journal.pone.0205180 ↗
61. 10.1074/jbc.M31149320010.1074/jbc.M311493200 ↗
62. 10.1038/s12276-020-0456-310.1038/s12276-020-0456-3 ↗
63. 10.1016/j.ebiom.2020.10279710.1016/j.ebiom.2020.102797 ↗
64. 10.1016/j.ebiom.2020.10282410.1016/j.ebiom.2020.102824 ↗
65. 10.4103/1673-5374.39097910.4103/1673-5374.390979 ↗
66. 10.1007/s00125-021-05387-610.1007/s00125-021-05387-6 ↗
67. 10.1152/ajpendo.00151.202110.1152/ajpendo.00151.2021 ↗
68. 10.1073/pnas.190367811610.1073/pnas.1903678116 ↗
69. 10.1038/s41467-019-11170-410.1038/s41467-019-11170-4 ↗
70. 10.1038/414807a10.1038/414807a ↗
71. 10.1042/BJ2008138610.1042/BJ20081386 ↗
72. 10.3390/ijms2204150910.3390/ijms22041509 ↗
73. 10.1016/j.redox.2017.01.01310.1016/j.redox.2017.01.013 ↗
74. 10.1074/jbc.M20970920010.1074/jbc.M209709200 ↗
75. 10.2337/db07-178110.2337/db07-1781 ↗
76. 10.1210/endo.140.8.690810.1210/endo.140.8.6908 ↗
77. Valdez, I. A.; Palavicini, J. P.; Bakewell, T. M.; Fourcaudot, M.; Ayala, I.; Xu, Z.; Khattab, A.; Han, X.; Shannon, C. E.; Norton, L. Persistent Inflammatory Lipotoxicity Impedes Pancreatic β-cell Function in Diet-Induced Obese Mice Despite Correction of Glucotoxicity bioRxiv 2022, 494168.10.1101/2022.05.31.494168.10.1101/2022.05.31.494168 ↗
78. 10.1152/ajpendo.00088.202010.1152/ajpendo.00088.2020 ↗
79. 10.1021/acs.iecr.9b0200310.1021/acs.iecr.9b02003 ↗
80. 10.1186/s12974-023-02866-y10.1186/s12974-023-02866-y ↗
81. 10.1002/advs.20220721410.1002/advs.202207214 ↗
82. 10.1002/btm2.1035010.1002/btm2.10350 ↗
83. Miladi K. · 2016 · 1710.1007/978-3-319-41421-8_2 ↗
84. 10.1021/acsbiomedchemau.2c0004810.1021/acsbiomedchemau.2c00048 ↗
85. Lo C. H. · 2021 · 121
86. 10.1016/j.jmb.2017.08.00910.1016/j.jmb.2017.08.009 ↗
87. 10.1080/15384047.2023.217669210.1080/15384047.2023.2176692 ↗
88. 10.1038/s41467-022-32346-510.1038/s41467-022-32346-5 ↗
89. 10.1007/978-1-4939-3578-9_510.1007/978-1-4939-3578-9_5 ↗
90. 10.3390/brainsci1309131810.3390/brainsci13091318 ↗
91. 10.1016/j.jpha.2023.06.01110.1016/j.jpha.2023.06.011 ↗
92. 10.1093/nar/gkac19410.1093/nar/gkac194 ↗
93. 10.1093/nar/28.1.2710.1093/nar/28.1.27 ↗
94. 10.1038/7555610.1038/75556 ↗
95. 10.1016/j.xpro.2020.10013210.1016/j.xpro.2020.100132 ↗
96. 10.1038/s41388-021-01832-310.1038/s41388-021-01832-3 ↗
97. 10.1016/j.bbrc.2017.02.10210.1016/j.bbrc.2017.02.102 ↗
98. 10.1016/j.acthis.2017.03.00110.1016/j.acthis.2017.03.001 ↗
99. 10.1016/j.xpro.2022.10140110.1016/j.xpro.2022.101401 ↗
100. 10.1083/jcb.20160303910.1083/jcb.201603039 ↗